Supernus Pharmaceuticals Inc
LSE:0LB2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
LSE:0LB2
|
US |
|
Lineage Inc
NASDAQ:LINE
|
US |
|
A-Living Smart City Services Co Ltd
OTC:ALVSF
|
CN |
|
Swisscom AG
F:SWJ
|
CH |
|
M
|
Marubeni Corp
XMUN:MARA
|
JP |
|
EMCOR Group Inc
NYSE:EME
|
US |
|
D
|
Dow Inc
SWB:2OY
|
US |
|
S
|
Sunstone Hotel Investors Inc
F:UF2
|
US |
|
U
|
UFP Technologies Inc
DUS:UFP
|
US |
|
Hanmi Financial Corp
NASDAQ:HAFC
|
US |
|
Lam Research Corp
NASDAQ:LRCX
|
US |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
CN |
|
Nippon Sanso Holdings Corp
F:NPX
|
JP |
|
P
|
PagerDuty Inc
SWB:2TY
|
US |
|
A
|
Agricultural Bank of China Ltd
XBER:EK7
|
CN |
|
Y
|
Yellow Cake PLC
OTC:YLLXF
|
JE |
|
African Rainbow Minerals Ltd
F:EB9
|
ZA |
|
Fluent Inc
NASDAQ:FLNT
|
US |
|
C
|
China Coal Energy Co Ltd
F:CVV
|
CN |
|
D
|
Digital Realty Trust Inc
SWB:FQI
|
US |
|
C
|
Caterpillar Inc
XBER:CAT1
|
US |
|
H
|
Halliburton Co
DUS:HAL
|
US |
|
D
|
Dominion Energy Inc
XBER:DOD
|
US |
|
F
|
Flowserve Corp
F:FWV
|
US |
Wall St Price Targets
0LB2 Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for 0LB2 is 63.45 USD with a low forecast of 54.99 USD and a high forecast of 68.6 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 0LB2's stock price target?
Price Target
63.45
USD
According to Wall Street analysts, the average 1-year price target for 0LB2 is 63.45 USD with a low forecast of 54.99 USD and a high forecast of 68.6 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
